EVLV:NASDAQEvolv Technologies Holdings, Inc. Analysis
Data as of 2026-05-19 - not real-time
$5.53
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Evolv Technologies (EVLV) trades at $5.53, well above its DCF fair value of $2.22, indicating an overvalued market price. Technicals show the stock is oversold (RSI 29) and sitting near its calculated support at $5.37, while the MACD remains bearish and the 20‑day SMA (6.65) sits above current price, suggesting limited upside in the near term. Volume is increasing and volatility remains high at ~56% over 30 days, with a beta above 1, reflecting a stock that can swing sharply on news.
Recent earnings calls highlight a strong revenue growth trajectory (+44.7% YoY) and a 2026 revenue outlook of $175‑$180 million, yet margins remain weak (gross margin ~50%, operating margin –18%) and earnings are negative. The balance sheet shows $61 M of cash versus $42 M of debt, providing a modest cushion, but the company’s price‑to‑book of 8.2× and lack of dividend underscore the valuation premium. Material news points to growing client satisfaction and a forthcoming investor day, which could boost sentiment, but the fundamental financial picture remains fragile.
Recent earnings calls highlight a strong revenue growth trajectory (+44.7% YoY) and a 2026 revenue outlook of $175‑$180 million, yet margins remain weak (gross margin ~50%, operating margin –18%) and earnings are negative. The balance sheet shows $61 M of cash versus $42 M of debt, providing a modest cushion, but the company’s price‑to‑book of 8.2× and lack of dividend underscore the valuation premium. Material news points to growing client satisfaction and a forthcoming investor day, which could boost sentiment, but the fundamental financial picture remains fragile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- RSI indicating oversold conditions
- Proximity to support level at $5.37
- Rising trading volume suggesting renewed interest
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong revenue growth guidance for 2026
- Improving cash flow versus modest debt load
- Continued margin compression and negative earnings
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Current price far above DCF fair value
- High volatility and beta increasing downside risk
- Lack of profitability and elevated valuation multiples
Key Metrics & Analysis
Financial Health
Revenue Growth44.70%
Profit Margin-22.75%
P/E Ratio-184.2
ROE-30.16%
ROA-5.79%
Debt/Equity34.78
P/B Ratio8.2
Op. Cash Flow$18.0M
Free Cash Flow$10.7M
Industry P/E29.2
Technical Analysis
TrendNeutral
RSI29.2
Support$5.37
Resistance$7.40
MA 20$6.65
MA 50$6.19
MA 200$6.79
MACDBearish
VolumeIncreasing
Fear & Greed Index89.14
Valuation
Fair Value$2.22
Target Price$10.13
Upside/Downside83.26%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.12
Volatility55.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.